[Skip to Content]
Access to paid content on this site is currently suspended due to excessive activity being detected from your IP address 54.197.171.35. Please contact the publisher to request reinstatement.
[Skip to Content Landing]
Article
October 1974

Protirelin (TRH) in Depression

Author Affiliations

From the Veterans Administration Hospital, Palo Alto, Calif (Drs. Hollister and Berger and Ms. Ogle); and the Veterans Administration Hospital, Danville, Ill (Drs. Arnold and Johnson).

Arch Gen Psychiatry. 1974;31(4):468-470. doi:10.1001/archpsyc.1974.01760160024006
Abstract

Protirelin (formally known as thyrotrophin releasing hormone [TRH]) was evaluated as a treatment in depression in two independent investigations using a similar protocol. The latter was designed so that some patients received three 600μg intravenous injections of protirelin early in their course and others received them toward the end of their course of treatment. Regardless of when protirelin was given in the course of depression, or how the course of the illness was measured, it seemed to be devoid both of therapeutic and of major adverse effects.

×